8-K

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

May28, 2024

Date

of Report (Date of earliest event reported)

EnvericBiosciences, Inc.

(Exactname of registrant as specified in its charter)

Delaware	001-38286	95-4484725
(State or other jurisdiction<br><br> <br>of incorporation)	(Commission<br><br> <br>File Number)	(I.R.S. Employer<br><br> <br>Identification No.)

EnvericBiosciences, Inc.

4851Tamiami Trail N, Suite 200

Naples,FL 34103

(Addressof principal executive offices) (Zip code)

Registrant’stelephone number, including area code: (239) 302-1707

N/A

(Formername or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common<br> stock, par value $0.01 per share	ENVB	The<br> Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item5.07 Submission of Matters to a Vote of Security Holders.

On May 28, 2024, Enveric Biosciences, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”). A total of 2,827,073 shares of the Company’s common stock were present in person or represented by proxy at the 2024 Annual Meeting, which represented 38.75% of the outstanding shares of common stock entitled to vote at the 2024 Annual Meeting and constituted a quorum for the transaction of business. Holders of the Company’s common stock were entitled to one vote per share of common stock held as of the close of business on April 1, 2024, the record date for the 2024 Annual Meeting. The matters submitted for a vote and the related results are set forth below. At the Annual Meeting, our stockholders voted on each of the following four matters:

●	The<br> election of six directors, to serve until the Company’s 2025 annual meeting of stockholders or until their successors are duly<br> elected and qualified (“Election of Directors”);
●	An<br> advisory vote to approve the compensation of the Company’s named executive officers, as disclosed in the proxy statement (the<br> “Say-on-Pay Proposal”);
●	The<br> ratification of the selection and appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal<br> year ending December 31, 2024 (the “Auditor Ratification Proposal”); and
●	An<br> advisory vote on whether the compensation of our named executive officers should occur every one year, every two years, or every<br> three years. (“Say-on-Frequency Proposal”).

The final vote results for each of these four matters is set forth below.

1. The votes cast on the Election of Directors were as follows:

Nominee	Votes For		Withheld		Broker Non-Votes
Michael D. Webb		767,013		107,751		1,952,309
George Kegler		509,016		365,748		1,952,309
Frank Pasqualone		523,495		351,269		1,952,309
Marcus Schabacker, M.D., Ph.D.		796,830		77,934		1,952,309
Joseph Tucker, Ph.D.		797,936		76,828		1,952,309
Sheila DeWitt, Ph.D		795,895		78,869		1,952,309

2. The votes cast on the advisory vote for the Say-on-Pay Proposal were as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
	711,513		116,232		47,019		1,952,309

3. The votes cast on the Auditor Ratification were as follows:

Votes For		Votes Against		Abstentions
	2,485,258		170,212		171,603

4. The votes cast on the advisory vote for the Say-on-Frequency Proposal were as follows:

One Year		Two Years		Three Years		Abstentions		Broker Non-Votes
	774,619		29,743		42,608		27,794		1,952,309

For more information about the foregoing proposals, please see the Company’s Proxy Statement for the 2024 Annual Meeting. The results reported above are final voting results. No other matters were considered or voted upon at the meeting.

---

Item9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit<br> Number	Description
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document)

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:<br> May 29, 2024	ENVERIC BIOSCIENCES, INC.
	By:	/s/ Joseph Tucker
		Joseph<br> Tucker, Ph.D.
		Chief<br> Executive Officer